Assert-IQ vs CVI42

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Assert-IQ

by Abbott

CVI42

by Circle Cardiovascular Imaging Inc.

AI Verdict

Assert-IQ is an insertable cardiac monitor system designed for long-term, continuous heart rhythm monitoring and arrhythmia detection. In contrast, CVI42 is an AI-enabled software platform specializing in comprehensive cardiac and vascular imaging analysis from CT and MRI scans. While both tools fall under Cardiology AI, they address distinct diagnostic needs: one for rhythm disorders and the other for structural and functional imaging assessment.

Choose Assert-IQ if…

Choose Assert-IQ if your primary need is long-term, continuous monitoring for suspected heart rhythm disorders that may be intermittent or difficult to capture with standard methods. This tool is ideal for extended arrhythmia detection and remote patient management, providing proactive alerts and patient-activated symptom logging over several years.

View Assert-IQ →

Choose CVI42 if…

Choose CVI42 if your focus is on advanced, AI-powered analysis of cardiac and vascular imaging data from CT and MRI scans. This platform is best suited for comprehensive diagnostic assessments, detailed plaque analysis, and precise treatment planning that requires sophisticated 3D visualization and automated contouring of regions of interest.

View CVI42 →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Assert-IQ	CVI42
Pricing	Unknown	Starts at $5,000 per license.
Deployment	Subcutaneously implanted device with mobile app connectivity	On-premise (standalone workstation or client/server)
FDA Status	Cleared AI-estimated	Cleared AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

CVI42

CVI42 offers a highly intuitive post-processing analysis and a comprehensive suite of tools for complex cardiac imaging, designed to streamline clinician workflows. Its vendor-independent nature and flexible deployment options (standalone, client/server, web viewer) enhance its adaptability and ease of integration into diverse clinical environments. Assert-IQ focuses more on patient convenience for remote monitoring and symptom logging, with dedicated support for setup.

Clinical Value

CVI42

CVI42 provides comprehensive, AI-driven analysis for cardiac and vascular imaging, including FDA-cleared coronary plaque quantification, which aids in precise diagnosis, risk stratification, and treatment planning. This depth of AI-powered diagnostic insight across multiple imaging modalities offers significant and immediate clinical impact. Assert-IQ delivers substantial value through long-term, continuous arrhythmia monitoring and improved AF diagnosis rates.

Pricing & Value

CVI42

While both require direct contact for pricing, CVI42 explicitly offers a 'flexible subscription that scales across CT and MR service lines' with additional licenses for specific modules. This modular and scalable pricing structure, designed to align with institutional needs and reimbursement, suggests a more adaptable and potentially value-optimized model. Assert-IQ's pricing details are less transparent beyond the device cost.

Enterprise Readiness

Assert-IQ

Assert-IQ benefits from being a product of Abbott Medical, a large and established global healthcare leader, providing inherent enterprise backing. It explicitly states HIPAA compliance and received FDA clearance for the device itself in May 2023. CVI42, while globally used and having FDA clearance for its plaque module, has 'not disclosed' HIPAA compliance or BAA status in the provided facts, which is a key consideration for enterprise adoption.

Innovation

CVI42

CVI42 demonstrates broader and deeper AI innovation by integrating extensive AI automation for complex cardiac and vascular imaging analysis across multiple modalities (CT, MRI), including advanced features like 4D flow pre-processing and research-use PCAT analysis. Its continuous expansion, such as integrating vascular CT analysis, showcases a wider application of cutting-edge AI. Assert-IQ is innovative for its long-term, remote, and AI-enhanced arrhythmia monitoring.

Support & Docs

CVI42

CVI42 receives strong positive user feedback for its 'great customer service' and reports 'industry-leading Net Promoter Score (NPS) and Customer Satisfaction (CSAT) feedback scores'. It also offers comprehensive documentation, help guides, webinars, and on-site training. Assert-IQ provides detailed manuals and dedicated remote monitoring support for patients.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Assert-IQ	CVI42
Product Name	Assert-IQ	CVI42
Company	Abbott Medical	CIRCLE CARDIOVASCULAR IMAGING
Primary Use Case	Long-term, continuous monitoring and advanced arrhythmia detection for suspected heart rhythm disorders.	Comprehensive cardiac and vascular imaging analysis (CT and MRI) for diagnosis, planning, and patient care.
Categories	Cardiology AI, Clinical Decision Support & Reference	Cardiology AI, Radiology & Imaging AI
Specialties Supported	Cardiology, Internal Medicine	Cardiology, Cardiothoracic Surgery, Radiology
Data Export Capability	Yes	Not specified

Videos

Demos, reviews, and walkthroughs featuring Assert-IQ and CVI42.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What is the primary clinical purpose of Assert-IQ compared to CVI42?

Assert-IQ is an Insertable Cardiac Monitor (ICM) system designed for long-term, continuous monitoring and advanced arrhythmia detection to help diagnose and manage patients with suspected heart rhythm disorders. CVI42 is an AI-enabled software platform for comprehensive cardiac and vascular imaging analysis, enhancing diagnosis, planning, and patient care with advanced CT and MRI tools.

What types of data do Assert-IQ and CVI42 primarily analyze?

Assert-IQ primarily analyzes continuous electrocardiogram (ECG) data from the insertable cardiac monitor to detect arrhythmias. CVI42 analyzes cardiac and vascular imaging data from CT and MRI scans, including coronary lumen and wall segmentation, plaque analysis, and advanced CMR automation.

What are the key differences in the AI capabilities of each tool?

Assert-IQ uses advanced AI algorithms primarily for arrhythmia detection, aiming to reduce false positives for AF and Pause episodes while maintaining high sensitivity. CVI42's AI capabilities focus on automated analysis of imaging data, including coronary lumen and wall segmentation, comprehensive coronary plaque analysis, and advanced CMR automation like T1 mapping and 4D flow pre-processing.

What is the typical monitoring or analysis duration/scope for each tool?

Assert-IQ provides long-term continuous cardiac monitoring with battery life options of at least three or six years. CVI42 offers comprehensive analysis of cardiac and vascular imaging studies, providing detailed insights into anatomy, function, and inflammation from CT and MRI scans, rather than continuous, long-term physiological monitoring.

What specialties are these tools best suited for?

Assert-IQ is primarily designed for Cardiology and Internal Medicine, focusing on patients with suspected heart rhythm disorders. CVI42 is suited for Cardiology, Cardiothoracic Surgery, and Radiology, supporting advanced cardiac and vascular imaging analysis.